ASH® 2025 Highlights: Presenter Vignette – Justin Ferdinandus
Justin Ferdinandus
MD
University of Cologne
152
Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
